Sign in Sign up for free

Last updated: 20 June 2019 at 3:04am EST

Thomas E Beier Net Worth




The estimated Net Worth of Thomas E Beier is at least $93.6 Thousand dollars as of 13 January 2017. Thomas Beier owns over 20,000 units of Opko Health Inc stock worth over $93,600 and over the last 17 years Thomas sold OPK stock worth over $0.

Thomas Beier OPK stock SEC Form 4 insiders trading

Thomas has made over 5 trades of the Opko Health Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Thomas exercised 20,000 units of OPK stock worth $41,000 on 13 January 2017.

The largest trade Thomas's ever made was exercising 29,773 units of Opko Health Inc stock on 30 December 2013 worth over $82,769. On average, Thomas trades about 6,667 units every 74 days since 2008. As of 13 January 2017 Thomas still owns at least 60,000 units of Opko Health Inc stock.

You can see the complete history of Thomas Beier stock trades at the bottom of the page.



What's Thomas Beier's mailing address?

Thomas's mailing address filed with the SEC is 100 NORTH CRESCENT DRIVE, , BEVERLY HILLS, CA, 90210.

Insiders trading at Opko Health Inc

Over the last 17 years, insiders at Opko Health Inc have traded over $862,245 worth of Opko Health Inc stock and bought 128,867,460 units worth $425,265,065 . The most active insiders traders include Phillip Md Et Al Frost Neva..., Phillip Md Et Al Frost Gamm..., and Phillip Md Et Al Frost Gamm.... On average, Opko Health Inc executives and independent directors trade stock every 4 days with the average trade being worth of $142,696. The most recent stock trade was executed by Phillip Md Et Al Frost Gamm... on 23 May 2024, trading 100,000 units of OPK stock currently worth $127,000.



What does Opko Health Inc do?

opko health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. our diagnostics business includes bioreference laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4kscore® prostate cancer test and the claros® 1 in office immunoassay platform. our pharmaceutical business features rayaldee, an fda approved treatment for shpt in stage 3-­4 ckd patients with vitamin d insufficiency (launched in november 2016), varubitm for chemotherapy induced nausea and vomiting (oral formulation launched by partner tesaro and iv formulation pending fda approval), opk88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in phase 2 clinical trials, among the new class of glp-­1 glucagon receptor dual agonists, and opk88003, a selective androgen receptor modulator for benig



What does Opko Health Inc's logo look like?

Opko Health Inc logo

Complete history of Thomas Beier stock trades at Opko Health Inc

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
13 Jan 2017 OPK Opko Health Inc Thomas E Beier
Director
 Option 20,000 $2.05 $41,000
13 Jan 2017
60,000 ↗
1 Apr 2016 OPK Opko Health Inc Thomas E Beier
Director
 Option 20,000 $1.54 $30,800
1 Apr 2016
40,000 ↗
17 Jul 2015 OPK Opko Health Inc Thomas E Beier
Director
 Option 20,000 $1.78 $35,600
17 Jul 2015
20,000 ↗
14 Nov 2014 OPK Opko Health Inc Thomas E Beier
Director
 Option 10,227 $2.78 $28,431
14 Nov 2014
30,227 ↗
30 Dec 2013 OPK Opko Health Inc Thomas E Beier
Director
 Option 29,773 $2.78 $82,769
30 Dec 2013
29,773 ↗


Opko Health Inc executives and stock owners

Opko Health Inc executives and other stock owners filed with the SEC include: